Abstract
Background We have previously estimated that respiratory syncytial virus (RSV) was associated with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in 55 000 to 199 000 deaths in children younger than 5 years in 2005. In the past 5 years, major research activity on RSV has yielded substantial new data from developing countries. With a considerably expanded dataset from a large international collaboration, we aimed to estimate the global incidence, hospital admission rate, and mortality from RSV-ALRI episodes in young children in 2015. Methods We estimated the incidence and hospital admission rate of RSV-associated ALRI (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions from a systematic review of studies published between Jan 1, 1995, and Dec 31, 2016, and unpublished data from 76 high quality population-based studies. We estimated the RSV-ALRI incidence for 132 developing countries using a risk factor-based model and 2015 population estimates. We estimated the in-hospital RSV-ALRI mortality by combining in-hospital case fatality ratios with hospital admission estimates from hospital-based (published and unpublished) studies. We also estimated overall RSV-ALRI mortality by identifying studies reporting monthly data for ALRI mortality in the community and RSV activity. Findings We estimated that globally in 2015, 33·1 million (uncertainty range [UR] 21·6–50·3) episodes of RSV-ALRI, resulted in about 3·2 million (2·7–3·8) hospital admissions, and 59 600 (48 000–74 500) in-hospital deaths in children younger than 5 years. In children younger than 6 months, 1·4 million (UR 1·2–1·7) hospital admissions, and 27 300 (UR 20 700–36 200) in-hospital deaths were due to RSV-ALRI. We also estimated that the overall RSV-ALRI mortality could be as high as 118 200 (UR 94 600–149 400). Incidence and mortality varied substantially from year to year in any given population. Interpretation Globally, RSV is a common cause of childhood ALRI and a major cause of hospital admissions in young children, resulting in a substantial burden on health-care services. About 45% of hospital admissions and in-hospital deaths due to RSV-ALRI occur in children younger than 6 months. An effective maternal RSV vaccine or monoclonal antibody could have a substantial effect on disease burden in this age group. Funding The Bill & Melinda Gates Foundation.
Original language | English |
---|---|
Pages (from-to) | 946-958 |
Number of pages | 13 |
Journal | The Lancet |
Volume | 390 |
Issue number | 10098 |
DOIs | |
Publication status | Published - 2 Sept 2017 |
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet, Vol. 390, No. 10098, 02.09.2017, p. 946-958.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015
T2 - a systematic review and modelling study
AU - for
AU - RSV Global Epidemiology Network
AU - Shi, Ting
AU - McAllister, David A.
AU - O'Brien, Katherine L.
AU - Simoes, Eric A.F.
AU - Madhi, Shabir A.
AU - Gessner, Bradford D.
AU - Polack, Fernando P.
AU - Balsells, Evelyn
AU - Acacio, Sozinho
AU - Aguayo, Claudia
AU - Alassani, Issifou
AU - Ali, Asad
AU - Antonio, Martin
AU - Awasthi, Shally
AU - Awori, Juliet O.
AU - Azziz-Baumgartner, Eduardo
AU - Baggett, Henry C.
AU - Baillie, Vicky L.
AU - Balmaseda, Angel
AU - Barahona, Alfredo
AU - Basnet, Sudha
AU - Bassat, Quique
AU - Basualdo, Wilma
AU - Bigogo, Godfrey
AU - Bont, Louis
AU - Breiman, Robert F.
AU - Brooks, W. Abdullah
AU - Broor, Shobha
AU - Bruce, Nigel
AU - Bruden, Dana
AU - Buchy, Philippe
AU - Campbell, Stuart
AU - Carosone-Link, Phyllis
AU - Chadha, Mandeep
AU - Chipeta, James
AU - Chou, Monidarin
AU - Clara, Wilfrido
AU - Cohen, Cheryl
AU - de Cuellar, Elizabeth
AU - Dang, Duc Anh
AU - Dash-yandag, Budragchaagiin
AU - Deloria-Knoll, Maria
AU - Dherani, Mukesh
AU - Eap, Tekchheng
AU - Ebruke, Bernard E.
AU - Echavarria, Marcela
AU - de Freitas Lázaro Emediato, Carla Cecília
AU - Fasce, Rodrigo A.
AU - Feikin, Daniel R.
AU - Feng, Luzhao
N1 - Funding Information: This study was funded by The Bill & Melinda Gates Foundation (OPP1088499; principal investigator: HN). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. HN and TS had full access to all the data in the study and HN had final responsibility for the decision to submit for publication. TS is supported by a scholarship from China Scholarship Council. DAM is funded via a Wellcome Trust Intermediate Clinical Fellowship (201492/Z/16/Z). HN, HC and LB are members of the Respiratory Syncytial Virus Consortium in Europe (RESCEU). RESCEU has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement N° 116019. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. Studies from Kilifi, Kenya received Wellcome Trust core funding (OXF-COR03). DJN and JAGS are supported by personal awards from the Wellcome Trust (102975, 098532). Data from Cape Town, South Africa, are funded by the Bill & Melinda Gates Foundation (OPP 1017641) and the MRC South Africa. The study from Vietnam by Nagasaki University is supported by the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) from Ministry of Education, Culture, Sport, Science, & Technology in Japan, and Japan Agency for Medical Research and Development (AMED). The funding agency does not have any role in writing the report. PB is an employee of GSK Vaccines. We acknowledge Leilei Huang and Huayu Zhang for preparing the maps of location of studies. Funding Information: This study was funded by The Bill & Melinda Gates Foundation ( OPP1088499 ; principal investigator: HN). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. HN and TS had full access to all the data in the study and HN had final responsibility for the decision to submit for publication. TS is supported by a scholarship from China Scholarship Council. DAM is funded via a Wellcome Trust Intermediate Clinical Fellowship (201492/Z/16/Z). HN, HC and LB are members of the Respiratory Syncytial Virus Consortium in Europe (RESCEU). RESCEU has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement N° 116019. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. Studies from Kilifi, Kenya received Wellcome Trust core funding (OXF-COR03). DJN and JAGS are supported by personal awards from the Wellcome Trust (102975, 098532). Data from Cape Town, South Africa, are funded by the Bill & Melinda Gates Foundation (OPP 1017641) and the MRC South Africa. The study from Vietnam by Nagasaki University is supported by the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) from Ministry of Education, Culture, Sport, Science, & Technology in Japan, and Japan Agency for Medical Research and Development (AMED). The funding agency does not have any role in writing the report. PB is an employee of GSK Vaccines. We acknowledge Leilei Huang and Huayu Zhang for preparing the maps of location of studies. Funding Information: Harish Nair, Harry Campbell, Ting Shi, Evelyn Balsells, Stuart Campbell (University of Edinburgh, Scotland, UK); David A McAllister (University of Glasgow, Scotland, UK); Asad Ali (Aga Khan University, Pakistan); Bradford D Gessner, Berthe-Marie Njanpop-Lafourcade, Jennifer C Moisi (Agence de Medecine Preventive, Paris, France); Anand Krishnan, Shobha Broor (All India Institute of Medical Sciences, New Delhi, India); Dana Bruden, Rosalyn Singleton (Arctic Investigations Program, Centres for Disease Control and Prevention, Anchorage, AK, USA); Angela Gentile, Florencia Lucion (Austral University and Ricardo Gutiérrez Children Hospital, Argentina); Budragchaagiin Dash-yandag (Bayanzurkh District General Hospital, Ulaanbaatar, Mongolia); Kunling Shen (Beijing Pediatric Research Institute, Beijing, China); Donald M Thea (Boston University School of Public Health, Boston, MA, USA); Hongjie Yu, Hui Jiang, Jiandong Zheng, Luzhao Feng (Center for Disease Control and Prevention, Beijing, China); Marietjie Venter (Centre for Viral Zoonosis, Department of Medical Virology, University of Pretoria, Pretoria, South Africa); Kim A Lindblade, Daniel R Feikin, Maurice O Ope, Deron C Burton (Centers for Disease Control and Prevention, Atlanta, GA, USA); Wilfrido Clara (Centers for Disease Control and Prevention, Central American Region, Guatemala City, Guatemala); Joel M Montgomery (Centers for Disease Control and Prevention, Nairobi, Kenya); Mala Rakoto-Andrianarivelo (Centre d'Infectiologie Charles Mérieux (CICM), Antananarivo, Madagascar); Chafiq Mahraoui (Centre Hospitalier Universitaire Ibn Sina Rabat, Morocco); Mamadou Sylla, Samba O Sow (Centre pour le Développement des Vaccins [CVD-Mali], Bamako, Mali); Debora N Marcone, Marcela Echavarria (Centro de Educación Médica e Investigaciones Clínicas “CEMIC”, Buenos Aires, Argentina); Sozinho Acacio, Betuel Sigauque (Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique); Barbara A Rath, Maren Alchikh (Charité University Medical Center, Berlin, Germany); Jianwei Wang (Chinese Academy of Medical Sciences, Beijing, China); Mariam Sylla (CHU Gabriel Touré, Bamako, Mali); Rafal Tokarz, Thomas Briese (Columbia University, New York, USA); Robert F Breiman (Emory Global Health Institute, Emory University, Atlanta, GA, USA); Lia N Phillips (Emory University, Rollins School of Public Health, Atlanta, GA, USA); Elizabeth D Thomas, Zeba A Rasmussen (Fogarty International Center Division of International Epidemiology and Population Studies, NIH, Bethesda, MD, USA); Fernando P Polack, Romina Libster (Fundacion INFANT, Buenos Aires, Argentina); Gláucia Paranhos-Baccalà, Florence Komurian-Pradel, Mélina Messaoudi, Valentina Sanchez Picot (GABRIEL network and Emerging Pathogens Laboratory, Fondation Mérieux, Lyon, France); Carla Cecília de Freitas Lázaro Emediato, Maria Tereza da Costa Oliveira (Health Secretariat of the City of Belo Horizonte, Belo Horizonte, Brazil); Annick Robinson (Hôpital Femme-Mère-Enfant, Antananarivo, Madagascar); Cinta Moraleda, Imane Jroundi, Rachid Benmessaoud, Lola Madrid, Miguel Lanaspa, Quique Bassat (ISGlobal, Barcelona Ctr Int Health Res (CRESIB), Hospital Clínic—Universitat de Barcelona, Barcelona, Spain); Claudia Aguayo, Ivan Rodriguez (Hospital Dr Guillermo Grant Benavente, Concepción, Chile); David Ortiz, Olga Lopez (Hospital Dr Ernesto Torres Galdames, Iquique, Chile); Alfredo Barahona (Hospital Materno Infantil Jose Domingo de Obaldia, Chiriqui, Panama); Philippe Buchy, Sophie Goyet, Veasna Duong (Institut Pasteur Cambodia, Phnom Penh, Cambodia); Koya Ariyoshi, Lay-Myint Yoshida (Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan); Graciela Russomando, Emilio E Espinola (Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asuncion, San Lorenzo, Paraguay); Eduardo Azziz-Baumgartner, Katharine Sturm-Ramirez, Stephen P Luby, Md Ziaur Rahman, W Abdullah Brooks, Doli Goswami, Mustafizur Rahman (International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh); Katherine L O'Brien, Maria Deloria-Knoll, (PERCH Study Group; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA); Siddhivinayak Hirve (KEM Hospital Research Center, Pune, India); Godfrey Bigogo (Kenya Medical Research Institute, Kisumu, Kenya); D James Nokes, Mwanajuma Ngama, Patrick Munywoki, J Anthony G Scott, Juliet O Awori, Susan Morpeth (Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya); Nitin Pandey, Shally Awasthi (King George's Medical University, Lucknow [UP], India); Claudia Turner, Paul Turner, Wanitda Watthanaworawit (Mahidol University, Mae Sot, Thailand); Grant MacKenzie, Stephen R C Howie, Bernard E Ebruke, Louis Peter Githua, Martin Antonio, Michel Dione (Medical Research Council Unit The Gambia, Basse, The Gambia); Cristiane Campos Monteiro (Minas Gerais Federal University, Belo Horizonte, Brazil); Wilma Basualdo (Ministerio de Salud Pública y Bienestar Social, San Lorenzo, Paraguay); Samir Faori (Ministry of Health, Amman, Jordan); Viviana Sotomayor (Ministry of Health, Chile); Elizabeth de Cuellar, Hector Ramos, Ivan Aparicio (Ministry of Health, El Salvador); Agustinus Sutanto (Ministry of Health, Indonesia); Angel Balmaseda, Guillermina Kuan (Ministry of Health, Managua, Nicaragua); Ericka Ferguson (Ministry of Health, Panama City, Panama); Issifou Alassani (Ministry of Health, Lome, Togo); Mario Mejia (Ministry of Public Health and Social Welfare, Guatemala City, Guatemala); Siripaporn Phuygun, Sunthareeya Waicharoen (Ministry of Public Health, Bangkok, Thailand); Pagbajabyn Nymadawa (Mongolian Academy of Medical Sciences, Ulaanbaatar, Mongolia); Cheryl Cohen, Jocelyn Moyes, Florette Treurnicht (National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa); Duc-Anh Dang, Nhat-Minh Le (National Institute of Hygiene and Epidemiology, Hanoi, Vietnam); Mandeep Chadha, Varsha A Potdar (National Institute of Virology, Pune, India); Tekchheng Eap (National Pediatric Hospital, Phnom Penh, Cambodia); Rodrigo A Fasce (Public Health Institute, Chile); Leilani T Nillos, Marilla G Lucero, Socorro P Lupisan (Research Institute for Tropical Medicine, Muntinlupa, Philippines); Brunhilde Schweiger (Robert Koch Institute [RKI], Berlin, Germany); Nathaly Gonzalez (Seremi de Salud de Tarapacá, Tarapacá, Chile); Andrea Gutierrez (Seremi de Salud Región del Bio Bio, Bio Bio, Chile); Vahid Salimi (Tehran University of Medical Sciences, Tehran, Iran); Charatdao Bunthi, Henry C Baggett, Patranuch Sapchookul, Pongpun Sawatwong, Sathapana Naorat, Somsak Thamthitiwat (Thailand Ministry of Public Health—US Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand); Histoshi Oshitani (Tohoku University Graduate School of Medicine, Miyagi Prefecture, Japan); Candice Romero, Yeny O Tinoco (US Naval Medical Research Unit No 6, Callao, Peru); Carmen Lucia Contreras, John P McCracken, Jorge Jara (Universidad del Valle de Guatemala, Guatemala City, Guatemala); Maria Mathisen (University Hospital of North Norway, Tromso, Norway); Louis Bont, Nienke Scheltema (University Medical Center Utrecht, Netherlands); Sudha Basnet, Tor A Strand (University of Bergen, Bergen, Norway); Eva Harris (University of California, Berkeley, CA, USA); Mark P Nicol (University of Cape Town and National Health Laboratory Services, Cape Town, South Africa); Heather J Zar (University of Cape Town, Cape Town, South Africa); Phyllis Carosone-Link, Eric A F Simoes (University of Colorado, Aurora, CO, USA); Monidarin Chou (University of Health Sciences, Phnom Penh, Cambodia); Najwa Khuri-Bulos (University of Jordan, Amman, Jordan); Nigel Bruce, Mukesh Dherani (University of Liverpool, Liverpool, UK); Karen L Kotloff, Milagritos D Tapia (University of Maryland School of Medicine, Baltimore, MD, USA); Aubree Gordon (University of Michigan, Ann Arbor, MI, USA); Phil Seidenberg (University of New Mexico, Albuquerque, NM, USA); Nusrat Homaira (University of New South Wales, Sydney, NSW, Australia); David Murdoch (University of Otago, Dunedin, New Zealand); Cissy B Kartasasmita, Kuswandewi Mutyara (University of Padjdjaran, Bandung, Indonesia); John Williams (University of Pittsburgh, Pittsburgh, PA, USA); Michelle Groome, Shabir A Madhi, Susan Nzenze, Azwifarwi Mudau, David P Moore, Peter V Adrian, Vicky L Baillie (University of the Witwatersrand, Johannesburg, South Africa); James Chipeta, Lawrence Mwanayanda (University Teaching Hospital, Lusaka, Zambia); Natasha Halasa (Vanderbilt University, Nashville, TN, USA); Christian Hoppe (Vienna Vaccine Safety Initiative [ViVI], Berlin, Germany); Peter F Wright (Dartmouth Medical School, Lebanon, NH, USA) Publisher Copyright: © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2017/9/2
Y1 - 2017/9/2
N2 - Background We have previously estimated that respiratory syncytial virus (RSV) was associated with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in 55 000 to 199 000 deaths in children younger than 5 years in 2005. In the past 5 years, major research activity on RSV has yielded substantial new data from developing countries. With a considerably expanded dataset from a large international collaboration, we aimed to estimate the global incidence, hospital admission rate, and mortality from RSV-ALRI episodes in young children in 2015. Methods We estimated the incidence and hospital admission rate of RSV-associated ALRI (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions from a systematic review of studies published between Jan 1, 1995, and Dec 31, 2016, and unpublished data from 76 high quality population-based studies. We estimated the RSV-ALRI incidence for 132 developing countries using a risk factor-based model and 2015 population estimates. We estimated the in-hospital RSV-ALRI mortality by combining in-hospital case fatality ratios with hospital admission estimates from hospital-based (published and unpublished) studies. We also estimated overall RSV-ALRI mortality by identifying studies reporting monthly data for ALRI mortality in the community and RSV activity. Findings We estimated that globally in 2015, 33·1 million (uncertainty range [UR] 21·6–50·3) episodes of RSV-ALRI, resulted in about 3·2 million (2·7–3·8) hospital admissions, and 59 600 (48 000–74 500) in-hospital deaths in children younger than 5 years. In children younger than 6 months, 1·4 million (UR 1·2–1·7) hospital admissions, and 27 300 (UR 20 700–36 200) in-hospital deaths were due to RSV-ALRI. We also estimated that the overall RSV-ALRI mortality could be as high as 118 200 (UR 94 600–149 400). Incidence and mortality varied substantially from year to year in any given population. Interpretation Globally, RSV is a common cause of childhood ALRI and a major cause of hospital admissions in young children, resulting in a substantial burden on health-care services. About 45% of hospital admissions and in-hospital deaths due to RSV-ALRI occur in children younger than 6 months. An effective maternal RSV vaccine or monoclonal antibody could have a substantial effect on disease burden in this age group. Funding The Bill & Melinda Gates Foundation.
AB - Background We have previously estimated that respiratory syncytial virus (RSV) was associated with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in 55 000 to 199 000 deaths in children younger than 5 years in 2005. In the past 5 years, major research activity on RSV has yielded substantial new data from developing countries. With a considerably expanded dataset from a large international collaboration, we aimed to estimate the global incidence, hospital admission rate, and mortality from RSV-ALRI episodes in young children in 2015. Methods We estimated the incidence and hospital admission rate of RSV-associated ALRI (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions from a systematic review of studies published between Jan 1, 1995, and Dec 31, 2016, and unpublished data from 76 high quality population-based studies. We estimated the RSV-ALRI incidence for 132 developing countries using a risk factor-based model and 2015 population estimates. We estimated the in-hospital RSV-ALRI mortality by combining in-hospital case fatality ratios with hospital admission estimates from hospital-based (published and unpublished) studies. We also estimated overall RSV-ALRI mortality by identifying studies reporting monthly data for ALRI mortality in the community and RSV activity. Findings We estimated that globally in 2015, 33·1 million (uncertainty range [UR] 21·6–50·3) episodes of RSV-ALRI, resulted in about 3·2 million (2·7–3·8) hospital admissions, and 59 600 (48 000–74 500) in-hospital deaths in children younger than 5 years. In children younger than 6 months, 1·4 million (UR 1·2–1·7) hospital admissions, and 27 300 (UR 20 700–36 200) in-hospital deaths were due to RSV-ALRI. We also estimated that the overall RSV-ALRI mortality could be as high as 118 200 (UR 94 600–149 400). Incidence and mortality varied substantially from year to year in any given population. Interpretation Globally, RSV is a common cause of childhood ALRI and a major cause of hospital admissions in young children, resulting in a substantial burden on health-care services. About 45% of hospital admissions and in-hospital deaths due to RSV-ALRI occur in children younger than 6 months. An effective maternal RSV vaccine or monoclonal antibody could have a substantial effect on disease burden in this age group. Funding The Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85021970644&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(17)30938-8
DO - 10.1016/S0140-6736(17)30938-8
M3 - Article
C2 - 28689664
AN - SCOPUS:85021970644
SN - 0140-6736
VL - 390
SP - 946
EP - 958
JO - The Lancet
JF - The Lancet
IS - 10098
ER -